FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311753777> ?p ?o ?g. }

• W4311753777 abstract "Abstract Background Novel SARS-CoV-2 (SCV2) variants may differ in epidemiology and clinical impact. PAIVED, a randomized trial comparing the efficacy of 3 different platforms of inactivated influenza vaccines in adult military health system beneficiaries, actively surveils participants for influenza-like illness (ILI), including COVID-19, and conducts targeted investigations among those who develop ILI. The current season (2021/22) offered an opportunity to assess symptomatology associated with emerging SCV2 variants in this prospective cohort. Methods Following receipt of influenza vaccine, PAIVED participants receive a weekly email or text message querying for ILI symptoms. Those who reported ILI completed a validated symptom diary (FLU-PRO Plus) daily for 7 days and collected a nasal swab. Nasal specimens underwent multiplex PCR testing, followed by SCV2 genome sequencing as applicable. PAIVED study participants from the 2021-22 influenza season who reported an ILI, had confirmed infection with SCV2 for which sequence data is available, and completed at least one FLU-PRO Plus survey were included in this analysis. Results To date, 293 participants (7% of active cohort; 22.5% reporting ILI) tested positive for SCV2; sequencing has identified 23 Delta and 200 Omicron variants (199 BA.1, 1 BA.2). Among the 212 participants with sequenced SCV2 and symptom data, 55% were male, 57% were white, and 85% were active-duty military (Table 1). Overall, peak symptom severity was classified as mild to moderate in 79.3% of cases, fever duration averaged 2.5±2.2 days, and there were activity limitations for a mean of 5.2±3.8 days. No differences in maximum symptom scores (total or by domain) were detected for participants infected with Omicron compared to Delta. Figure 1 depicts variation in mean symptom scores by day of ILI, grouped by variant. Table 1.Demographic characteristics of PAIVED study participants with Delta and Omicron SARS-CoV-2 variants during the 2021/22 season.Figure 1.Mean FLU-PRO Plus domain and total scores by days since identification of an influenza-like illness in participants with Omicron or Delta variants of SARS-CoV-2 in the 2021/22 season of PAIVED. Conclusion Omicron emerged as the predominant SCV2 variant causing ILI in our cohort this season, typically manifesting with mild symptoms. Further exploration of potential differences in ILI experience between SCV2 variants and other ILI causes, plus the impact and timing of vaccination, will add insight into the relative contribution of such factors on symptomatology. Disclosures John H. Powers, III, MD, Arrevus: Advisor/Consultant|Eicos: Advisor/Consultant|Evofem: Advisor/Consultant|Eyecheck: Advisor/Consultant|Gilead: Advisor/Consultant|GlaxoSmithKline: Advisor/Consultant|OPKO: Advisor/Consultant|Resolve: Advisor/Consultant|Romark: Advisor/Consultant|SpineBioPharma: Advisor/Consultant|UTIlity: Advisor/Consultant|Vir: Advisor/Consultant Jitendrakumar Modi, MD, GlaxoSmithKline: I am a paid speaker for GSK. I do not speak for their flu brand. Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response." @default.
• W4311753777 created "2022-12-28" @default.
• W4311753777 creator A5000166462 @default.
• W4311753777 creator A5004447215 @default.
• W4311753777 creator A5006735041 @default.
• W4311753777 creator A5007293184 @default.
• W4311753777 creator A5007853642 @default.
• W4311753777 creator A5009912008 @default.
• W4311753777 creator A5010496694 @default.
• W4311753777 creator A5010747799 @default.
• W4311753777 creator A5010911816 @default.
• W4311753777 creator A5014967959 @default.
• W4311753777 creator A5015331279 @default.
• W4311753777 creator A5017998675 @default.
• W4311753777 creator A5033862179 @default.
• W4311753777 creator A5043112234 @default.
• W4311753777 creator A5044388477 @default.
• W4311753777 creator A5045602329 @default.
• W4311753777 creator A5059536572 @default.
• W4311753777 creator A5059548038 @default.
• W4311753777 creator A5078188326 @default.
• W4311753777 creator A5086592075 @default.
• W4311753777 date "2022-12-01" @default.
• W4311753777 modified "2023-09-30" @default.
• W4311753777 title "273. Emergence of the SARS-CoV-2 Omicron Variant in the Pragmatic Assessment of Influenza Vaccine Effectiveness in the Department of Defense (PAIVED) Study" @default.
• W4311753777 doi "https://doi.org/10.1093/ofid/ofac492.351" @default.
• W4311753777 hasPublicationYear "2022" @default.
• W4311753777 type Work @default.
• W4311753777 citedByCount "0" @default.
• W4311753777 crossrefType "journal-article" @default.
• W4311753777 hasAuthorship W4311753777A5000166462 @default.
• W4311753777 hasAuthorship W4311753777A5004447215 @default.
• W4311753777 hasAuthorship W4311753777A5006735041 @default.
• W4311753777 hasAuthorship W4311753777A5007293184 @default.
• W4311753777 hasAuthorship W4311753777A5007853642 @default.
• W4311753777 hasAuthorship W4311753777A5009912008 @default.
• W4311753777 hasAuthorship W4311753777A5010496694 @default.
• W4311753777 hasAuthorship W4311753777A5010747799 @default.
• W4311753777 hasAuthorship W4311753777A5010911816 @default.
• W4311753777 hasAuthorship W4311753777A5014967959 @default.
• W4311753777 hasAuthorship W4311753777A5015331279 @default.
• W4311753777 hasAuthorship W4311753777A5017998675 @default.
• W4311753777 hasAuthorship W4311753777A5033862179 @default.
• W4311753777 hasAuthorship W4311753777A5043112234 @default.
• W4311753777 hasAuthorship W4311753777A5044388477 @default.
• W4311753777 hasAuthorship W4311753777A5045602329 @default.
• W4311753777 hasAuthorship W4311753777A5059536572 @default.
• W4311753777 hasAuthorship W4311753777A5059548038 @default.
• W4311753777 hasAuthorship W4311753777A5078188326 @default.
• W4311753777 hasAuthorship W4311753777A5086592075 @default.
• W4311753777 hasBestOaLocation W43117537771 @default.
• W4311753777 hasConcept C104317684 @default.
• W4311753777 hasConcept C126322002 @default.
• W4311753777 hasConcept C141231307 @default.
• W4311753777 hasConcept C159047783 @default.
• W4311753777 hasConcept C185592680 @default.
• W4311753777 hasConcept C187212893 @default.
• W4311753777 hasConcept C203014093 @default.
• W4311753777 hasConcept C22070199 @default.
• W4311753777 hasConcept C24432333 @default.
• W4311753777 hasConcept C2522874641 @default.
• W4311753777 hasConcept C2776289493 @default.
• W4311753777 hasConcept C2777870961 @default.
• W4311753777 hasConcept C2779134260 @default.
• W4311753777 hasConcept C2779954635 @default.
• W4311753777 hasConcept C3008058167 @default.
• W4311753777 hasConcept C524204448 @default.
• W4311753777 hasConcept C55493867 @default.
• W4311753777 hasConcept C71924100 @default.
• W4311753777 hasConcept C72563966 @default.
• W4311753777 hasConcept C89623803 @default.
• W4311753777 hasConceptScore W4311753777C104317684 @default.
• W4311753777 hasConceptScore W4311753777C126322002 @default.
• W4311753777 hasConceptScore W4311753777C141231307 @default.
• W4311753777 hasConceptScore W4311753777C159047783 @default.
• W4311753777 hasConceptScore W4311753777C185592680 @default.
• W4311753777 hasConceptScore W4311753777C187212893 @default.
• W4311753777 hasConceptScore W4311753777C203014093 @default.
• W4311753777 hasConceptScore W4311753777C22070199 @default.
• W4311753777 hasConceptScore W4311753777C24432333 @default.
• W4311753777 hasConceptScore W4311753777C2522874641 @default.
• W4311753777 hasConceptScore W4311753777C2776289493 @default.
• W4311753777 hasConceptScore W4311753777C2777870961 @default.
• W4311753777 hasConceptScore W4311753777C2779134260 @default.
• W4311753777 hasConceptScore W4311753777C2779954635 @default.
• W4311753777 hasConceptScore W4311753777C3008058167 @default.
• W4311753777 hasConceptScore W4311753777C524204448 @default.
• W4311753777 hasConceptScore W4311753777C55493867 @default.
• W4311753777 hasConceptScore W4311753777C71924100 @default.
• W4311753777 hasConceptScore W4311753777C72563966 @default.
• W4311753777 hasConceptScore W4311753777C89623803 @default.
• W4311753777 hasIssue "Supplement_2" @default.
• W4311753777 hasLocation W43117537771 @default.
• W4311753777 hasOpenAccess W4311753777 @default.
• W4311753777 hasPrimaryLocation W43117537771 @default.
• W4311753777 hasRelatedWork W2027490722 @default.
• W4311753777 hasRelatedWork W2212772714 @default.
• W4311753777 hasRelatedWork W2238496498 @default.
• W4311753777 hasRelatedWork W2255191231 @default.
• W4311753777 hasRelatedWork W2329152519 @default.

• next